Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $74.32 today, the market must believe free cash flow compounds 10.0%/yr for a decade (off $139.9M on the 3-yr avg basis).
On the basis ($126.3M) the requirement is 11.4%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 10.0% is more conservative than its 9-yr track record.
Default is 9.3% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.03B shares (market data) · net debt $1.13B
mean 52.9% · volatility σ 150% · implied rate exceeded in 4/9 yrs
Central path = implied 10.0%/yr growth; shaded band = ±1σ (150%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $56.3M buybacks = $56.3M returned on $273.5M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -13%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~6.5% on $1.21B of debt.
Cash of $78.1M fully covers short-term debt of $47.1M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.17B 100.0% | $1.20B 100.0% | $1.22B 100.0% | $1.67B 100.0% | $1.39B 100.0% | $1.22B 100.0% | $1.29B 100.0% | $1.13B 100.0% | $972.4M 100.0% | $908.3M 100.0% |
| Cost of Revenue | $706.1M 60.5% | $735.3M 61.3% | $770.5M 63.4% | $1.10B 65.8% | $878.7M 63.1% | $750.6M 61.7% | $810.9M 62.7% | $716.8M 63.2% | $643.4M 66.2% | $633.9M 69.8% |
| Cost of Products | — | — | — | — | — | — | — | — | $643.4M 66.2% | $633.9M 69.8% |
| Gross Profit | $461.5M 39.5% | $464.8M 38.7% | $445.0M 36.6% | $570.1M 34.2% | $512.8M 36.9% | $465.5M 38.3% | $482.0M 37.3% | $416.8M 36.8% | $329.0M 33.8% | $274.4M 30.2% |
| Research & Development | $28.4M 2.4% | $24.5M 2.0% | $25.4M 2.1% | $30.3M 1.8% | $26.3M 1.9% | $22.6M 1.9% | $19.7M 1.5% | $21.5M 1.9% | $19.8M 2.0% | $17.6M 1.9% |
| Selling, General & Admin | $171.2M 14.7% | $157.8M 13.1% | $161.8M 13.3% | $198.8M 11.9% | $179.3M 12.9% | $149.4M 12.3% | $163.1M 12.6% | $132.4M 11.7% | $106.4M 10.9% | $96.4M 10.6% |
| Operating Income | $418.7M 35.9% | $425.9M 35.5% | $423.2M 34.8% | $452.6M 27.1% | $422.2M 30.3% | $397.9M 32.7% | $396.9M 30.7% | $320.5M 28.3% | $242.7M 25.0% | $163.6M 18.0% |
| Interest Expense | $78.3M 6.7% | $97.8M 8.1% | $93.3M 7.7% | $61.8M 3.7% | $51.7M 3.7% | $47.1M 3.9% | $54.6M 4.2% | $33.2M 2.9% | $18.1M 1.9% | $19.3M 2.1% |
| Interest & Investment Income | $5.2M 0.4% | $7.7M 0.6% | $6.3M 0.5% | $7.5M 0.4% | $4.0M 0.3% | $4.9M 0.4% | $7.7M 0.6% | $3.4M 0.3% | $2.3M 0.2% | — |
| Other Income (Expense), net | -$25.0M -2.1% | -$7.9M -0.7% | $16.2M 1.3% | $1.7M 0.1% | -$79.9M -5.7% | $4.1M 0.3% | $4.3M 0.3% | -$1.0M -0.1% | -$500K -0.1% | $3.2M 0.4% |
| Pretax Income | -$142.1M -12.2% | -$140.5M -11.7% | $130.0M 10.7% | $269.6M 16.2% | $162.8M 11.7% | $235.1M 19.3% | $227.9M 17.6% | $221.8M 19.6% | $174.8M 18.0% | $87.0M 9.6% |
| Income Tax Expense | $8.2M 0.7% | -$19.1M -1.6% | $24.2M 2.0% | $58.0M 3.5% | $44.7M 3.2% | $53.7M 4.4% | $44.2M 3.4% | $40.0M 3.5% | $29.6M 3.0% | $42.6M 4.7% |
| Net Income | -$167.1M -14.3% | -$430.3M -35.9% | -$5.4M -0.4% | $211.6M 12.7% | $118.1M 8.5% | $181.4M 14.9% | $183.7M 14.2% | $169.1M 14.9% | $126.5M 13.0% | $35.2M 3.9% |
| Per Share | ||||||||||
| EPS (Basic) | -$4.61 | -$11.85 | -$0.15 | $5.54 | $2.97 | $4.39 | $4.39 | $4.02 | $3.00 | $0.83 |
| EPS (Diluted) | -$4.61 | -$11.85 | -$0.15 | $5.50 | $2.95 | $4.37 | $4.35 | $3.97 | $2.97 | $0.83 |
| Weighted Avg Shares (Basic) | 36.2M | 36.3M | 36.5M | 38.2M | 39.8M | 41.3M | 41.8M | 42.0M | 42.1M | 42.1M |
| Weighted Avg Shares (Diluted) | 36.2M | 36.3M | 36.7M | 38.5M | 40.1M | 41.5M | 42.2M | 42.6M | 42.5M | 42.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 39 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| INDV | $4.2B | 21.6× | 15.8× | 3.4× | 4.3% | 80.2% | 16.9% | -214% | 95.0% | 0.5× | 52 |
| ARQT | $4.0B | — | — | 10.7× | 91.3% | 90.2% | -4.3% | -8.5% | -5.4% | — | 50 |
| AVNT | $3.9B | 48.1× | 15.0× | 1.2× | 0.6% | 31.2% | 2.5% | 3.4% | 1.9% | 4.9× | 64 |
| CBT | $3.8B | 12.4× | 5.8× | 1.0× | -7.0% | 25.3% | 8.9% | 21.4% | 13.7% | 0.8× | 86 |
| IOVA | $3.8B | — | — | 14.6× | 60.6% | 34.3% | -148% | -56.0% | -56.0% | — | 50 |
| IPAR | $3.7B | 22.2× | 13.1× | 2.5× | 2.5% | 63.6% | 11.3% | 19.1% | 16.6% | 0.4× | 61 |
| OGN | $3.6B | 19.2× | — | 0.6× | -2.9% | 53.3% | 3.0% | 24.9% | 2.0% | — | 150 |
| SMG | $3.6B | 25.2× | 13.5× | 1.1× | -3.9% | 30.6% | 4.3% | -40.6% | 8.3% | 4.9× | 100 |
| ACAD | $3.5B | 8.9× | 31.9× | 3.3× | 11.9% | 91.7% | 36.5% | 31.9% | 31.9% | -1.7× | 61 |
| BHC | $3.1B | 19.5× | 11.2× | 0.3× | 6.7% | — | 1.5% | -28.3% | 0.8% | 9.7× | 35 |
| COTY | $3.0B | — | 14.6× | 0.5× | -1.5% | 62.9% | -10.4% | -20.2% | -10.0% | 7.2× | 62 |
| WDFC | $3.0B | 33.0× | 26.6× | 4.8× | 5.0% | 55.1% | 14.7% | 33.9% | 25.6% | 0.3× | 67 |
| ZLAB | $2.7B | — | — | 6.0× | 15.3% | 58.6% | -38.1% | -24.5% | -19.1% | — | 8 |
| FUL | $2.7B | 18.1× | 12.9× | 0.8× | -2.7% | 31.1% | 4.4% | 7.6% | 3.8% | 5.4× | 67 |
| NEOG | $2.6B | — | 33.7× | 3.0× | -2.7% | 46.9% | -0.9% | -0.4% | -0.3% | 6.4× | 61 |
| ADMA | $2.6B | 19.0× | 12.7× | 5.0× | 19.6% | 57.4% | 28.8% | 30.8% | 26.7% | -0.1× | 72 |
| NGVT | $2.6B | — | 7.0× | 2.2× | -2.7% | 39.5% | -14.3% | -563% | -13.5% | 2.1× | 84 |
| IOSP | $2.5B | 21.4× | 12.5× | 1.4× | -3.7% | 27.7% | 6.6% | 8.8% | 8.8% | -1.7× | 57 |
| SUPN | $2.4B | — | 79.0× | 3.4× | 8.6% | 89.6% | -5.4% | -3.6% | -3.6% | -4.4× | 60 |
| RXRX | $2.4B | — | — | 32.3× | 26.9% | 5.0% | -863% | -57.0% | -56.1% | — | 63 |
| ROG | $2.4B | — | — | 2.9× | -2.3% | 31.7% | -7.6% | -5.2% | -5.2% | — | 54 |
| PBH | $2.3B | 12.6× | 9.6× | 2.1× | -4.3% | 54.7% | 17.5% | 10.1% | 6.6% | 2.7× | 57 |
| HCM | $2.3B | 25.3× | — | 4.2× | -13.0% | 38.7% | 83.3% | 36.9% | 34.3% | — | 8 |
| HRMY | $2.3B | 14.3× | — | 2.6× | 21.5% | 77.2% | 18.3% | 18.2% | 15.3% | — | 67 |
| AUPH | $2.2B | 8.0× | 17.2× | 7.8× | 20.4% | 88.5% | — | 49.4% | 49.4% | -0.6× | 41 |
Peers = companies sharing NGVT's sector (Chemicals & Allied Products) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
EOD close · as of 2026-10-30
Where each multiple sits in its own 10-yr range · 67th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 10-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE -563% against ROIC -13% — -549% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -148.6% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 63.2 | 62.7 | 61.7 | 63.1 | 65.8 | 63.4 | 61.3 | 60.5 |
| Gross Profit | 36.8 | 37.3 | 38.3 | 36.9 | 34.2 | 36.6 | 38.7 | 39.5 |
| R&D | 1.9 | 1.5 | 1.9 | 1.9 | 1.8 | 2.1 | 2.0 | 2.4 |
| SG&A | 11.7 | 12.6 | 12.3 | 12.9 | 11.9 | 13.3 | 13.1 | 14.7 |
| Operating Income | 28.3 | 30.7 | 32.7 | 30.3 | 27.1 | 34.8 | 35.5 | 35.9 |
| Income Tax | 3.5 | 3.4 | 4.4 | 3.2 | 3.5 | 2.0 | -1.6 | 0.7 |
| Net Income | 14.9 | 14.2 | 14.9 | 8.5 | 12.7 | -0.4 | -35.9 | -14.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on NGVT: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Earns 15.82pts above its cost of capital, but net margin has stepped down from 1268.36% to -1431.14% over 3 years.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 17.0% | 9.3% (today's — no rate published for this year) | 7.7pts |
| FY2020 | 17.6% | 9.3% (today's — no rate published for this year) | 8.3pts |
| FY2021 | 18.7% | 7.2% | 11.5pts |
| FY2022 | 16.0% | 7.2% | 8.9pts |
| FY2023 | 15.7% | 7.6% | 8.1pts |
| FY2024 | 20.6% | 9.7% | 10.9pts |
| FY2025 | 26.6% | 9.3% | 17.3pts |
| Now | -13.5% | 9.3% | -22.8pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 30.2% | 18.0% | 3.9% |
| FY2017 | 33.8% | 25.0% | 13.0% |
| FY2018 | 36.8% | 28.3% | 14.9% |
| FY2019 | 37.3% | 30.7% | 14.2% |
| FY2020 | 38.3% | 32.7% | 14.9% |
| FY2021 | 36.9% | 30.3% | 8.5% |
| FY2022 | 34.2% | 27.1% | 12.7% |
| FY2023 | 36.6% | 34.8% | -0.4% |
| FY2024 | 38.7% | 35.5% | -35.9% |
| FY2025 | 39.5% | 35.9% | -14.3% |
Return on equity is 549 points BELOW the return on invested capital, which means the equity base is carrying capital the operations are not earning on — usually cash, goodwill, or a recent raise.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
$4M of goodwill — 0% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer.
Net margin is -1431.14% against 1268.36% 3 years ago — a step down the business has not recovered, whatever the spread says today.
Converts 1.19x of reported profit into free cash flow over 4 years, with accruals negative.
Capex has been below depreciation for 3 consecutive years (0.88x on average over the last 5). Spending less than the asset base is consuming flatters free cash flow now and defers the cost — though depreciation also covers amortisation of acquired intangibles, which capex is not meant to replace.
Covers interest 3.7x under stress — adequate, without much room.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 5.35x |
| 5% | 5.08x |
| 10% | 4.81x |
| 15% | 4.55x |
| 20% | 4.28x |
| 25% | 4.01x |
| 30% | 3.74x |
| 35% | 3.48x |
| 40% | 3.21x |
| 45% | 2.94x |
| 50% | 2.67x |
| 55% | 2.41x |
| 60% | 2.14x |
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Coverage is comfortable at 5.3x today but falls to 3.7x after a 30% EBITDA decline — the cushion is earnings, not liquidity.
At $74.32, free cash flow must compound 10.12%/yr for 10 years. It has done 9.24%/yr over 6 years, though across a reporting-basis change.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | 68.0% | 10.1% |
| FY2021 | −29.9% | 10.1% |
| FY2022 | −9.8% | 10.1% |
| FY2023 | −44.2% | 10.1% |
| FY2024 | −46.5% | 10.1% |
| FY2025 | 436.3% | 10.1% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The achieved growth rate spans a reporting-basis change in FY2023, so part of it measures the restatement rather than the business.
| Step | Amount | Running total |
|---|---|---|
| Net income | −$167M | −$167M |
| Share-based comp | $18M | −$149M |
| Other non-cash & working capital | $480M | $331M |
| Operating cash flow | $331M | $331M |
| Capex | −$58M | $274M |
| Free cash flow | $274M | $274M |
| FCF after SBC | $255M | $255M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | -5.9% | -1.3% | 4.6 points |
| FY2021 | 14.4% | not reported | not reported |
| FY2022 | 19.9% | not reported | not reported |
| FY2023 | -27.1% | not reported | not reported |
| FY2024 | -1.3% | not reported | not reported |
| FY2025 | -2.7% | not reported | not reported |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 42.3 days | 95.6 days | 44.6 days | 93.4 days |
| FY2020 | 44.4 days | 91.9 days | 50.7 days | 85.7 days |
| FY2021 | not reported | 100.2 days | 52.3 days | not reported |
| FY2022 | not reported | 111.3 days | 58.1 days | not reported |
| FY2023 | not reported | 146.3 days | 75 days | not reported |
| FY2024 | not reported | 97.2 days | 46.9 days | not reported |
| FY2025 | not reported | 96.1 days | 47.6 days | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -4.3 percent |
| FY2020 | -7.3 percent |
| FY2021 | -7.1 percent |
| FY2022 | -3.7 percent |
| FY2023 | -8.0 percent |
| FY2024 | -27.6 percent |
| FY2025 | -30.2 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 3 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Segal Francis David Director | Grant | 335 | $71.09 | $24k |
| 2026-10-01 | Willis J Kevin Director | Grant | 405 | $71.09 | $29k |
| 2026-08-18 | 3 co-filers President & CEO | 10b5-1 plan sale | 92 | $74.71 | $7k |
| 2026-08-17 | 3 co-filers President & CEO | 10b5-1 plan sale | 5,000 | $75.83 | $379k |
| 2026-08-14 | 3 co-filers President & CEO | 10b5-1 plan sale | 5,000 | $75.73 | $379k |
| 2026-08-13 | 2 co-filers President & CEO | 10b5-1 plan sale | 5,000 | $75.73 | $379k |
| 2026-08-12 | 2 co-filers President & CEO | 10b5-1 plan sale | 5,000 | $76.62 | $383k |
| 2026-08-10 | Platt Phillip John SVP, Chief Financial Officer | Tax withholding | 1,698 | $77.04 | $131k |
| 2026-08-03 | 2 co-filers SVP, Gen. Counsel & Secretary | Open-market sale | 1,397 | $73.76 | $103k |
| 2026-08-03 | 2 co-filers SVP, Gen. Counsel & Secretary | Open-market sale | 1,312 | $73.67 | $97k |
| 2026-07-24 | Platt Phillip John SVP, Chief Financial Officer | Tax withholding | 3,294 | $73.26 | $241k |
| 2026-07-06 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withholding | 168 | $73.86 | $12k |
| 2026-07-01 | Segal Francis David Director | Grant | 328 | $72.58 | $24k |
| 2026-07-01 | Willis J Kevin Director | Grant | 397 | $72.58 | $29k |
| 2026-06-22 | Cotterman Ryan Joseph VP, Chief Accounting Officer | Grant | 2,063 | $0.00 | $0 |
| 2026-05-28 | 3 co-filers SVP, Chief HR Officer | Open-market sale | 266 | $68.45 | $18k |
| 2026-05-28 | 3 co-filers SVP, Chief HR Officer | Open-market sale | 30 | $68.57 | $2k |
| 2026-05-28 | 3 co-filers SVP, Chief HR Officer | Open-market sale | 200 | $68.53 | $14k |
| 2026-05-01 | Platt Phillip John SVP, Finance & CAO | Grant | 1,262 | $0.00 | $0 |
| 2026-04-30 | Segal Francis David Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Wright Benjamin G. Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Fernandez-Moreno Luis M Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Gulyas Diane H. Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Lynch Frederick J Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Willis J Kevin Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Hoechner Bruce D. Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-30 | Narwold Karen G Director | Grant | 1,904 | $0.00 | $0 |
| 2026-04-07 | 2 co-filers President & CEO | Tax withholding | 13,102 | $70.57 | $925k |
| 2026-04-07 | 2 co-filers President & CEO | Tax withholding | 3,574 | $70.57 | $252k |
| 2026-04-01 | Segal Francis David Director | Grant | 329 | $72.28 | $24k |
| 2026-04-01 | Willis J Kevin Director | Grant | 398 | $72.28 | $29k |
| 2026-03-25 | Fisher Ryan C. SVP, Gen. Counsel & Secretary | Tax withholding | 308 | $71.78 | $22k |
| 2026-03-02 | 4 co-filers EVP, Chief Financial Officer | Tax withholding | 747 | $71.64 | $54k |
| 2026-03-02 | 4 co-filers SVP and Pres, Perf Chemicals | Tax withholding | 351 | $71.64 | $25k |
| 2026-03-02 | 5 co-filers SVP, Gen. Counsel & Secretary | Tax withholding | 195 | $71.64 | $14k |
| 2026-03-02 | 5 co-filers SVP, Operations | Tax withholding | 143 | $71.64 | $10k |
| 2026-03-02 | 4 co-filers SVP and Pres, Perf Chemicals | Tax withholding | 617 | $71.64 | $44k |
| 2026-03-02 | 5 co-filers SVP, Finance & CAO | Tax withholding | 224 | $71.64 | $16k |
| 2026-03-02 | 4 co-filers EVP, Chief Financial Officer | Tax withholding | 1,363 | $71.64 | $98k |
| 2026-03-02 | 2 co-filers SVP, Chief HR Officer | Tax withholding | 550 | $71.64 | $39k |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.